During the last IMPAKT breast cancer conference, breast cancer specialists from the BIG network animated a panel on the following subject: "…read more
The 7th edition of IMPAKT will take place from 7 to 9 May 2015 in Brussels. Organised by the Breast International Group (BIG) and the Europe…read more
In support of a global research programme for metastatic breast cancer, Dr. Carlo Bock, president of the ‘Fondation Cancer’ of Luxembourg an…read more
Each year, all BIG members convene for the General Assembly to review the past year's results, consider new member applications and propose …read more
In In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb®)…read more
The aromatase inhibitor exemestane is more effective than tamoxifen in preventing breast cancer recurrence in young women who also receive o…read more
The 5th issue of the newsletter highlights some of INTEGRATE's most recent achievements, with an emphasis on the development and fine tuning…read more
AURORA is the first international research programme aiming to improve the lives of advanced breast cancer patients. It was launched on 15 A…read more
Great progress has been made, but cancer incidence continues to grow. In Western countries, research and screening programs have successfully reduced the mortality rate but the number of patients diagnosed has actually increased over time (+66% since 1975). Today, a woman’s chance of getting breast cancer is 1 in 8.
Chaired by Dr Martine Piccart and Dr Aron Goldhirsch, BIG’s mission is to facilitate breast cancer research internationally. To fulfil its mission, BIG can count on a network of more than 3.000 hospitals and more than 10.000 doctors and researchers!
AURORA, a Metastatic breast cancer GPS
Academic programme “AURORA” (previously called PRISM-BC)
Metastatic cancer represents the leading cause of death among breast cancer patients, and little progress has been made until now. By using the latest technologies to “molecularly screen” patients tumours, the GPS project aims to analyse the mechanisms of resistance to treatment (why some patients’ tumours respond poorly), to understand the sensitivity to treatment (why some patients’ tumours respond well) and to track the natural progression of the disease. This will be the first large-scale international programme of its kind to focus on metastatic breast cancer, in the hope of significantly improving patients’ lives.
Finding a cure for breast cancer is one of the biggest challenges faced by researchers from around the world.
Significant progress has been made to improve both the chances of survival and the quality of life of women affected by the disease. However, breast cancer remains the second most common cancer in the world and is still responsible for too many deaths annually.
By bringing together the top breast cancer experts from around the world to conduct innovative research, BIG has the global reach and expertise required to find a cure. We need to support such critical research to give hope to women affected by this devastating disease, and their families.
HER MAJESTY THE QUEEN OF THE BELGIANS